Home   Package List   Routine Alphabetical List   Global Alphabetical List   FileMan Files List   FileMan Sub-Files List   Package Component Lists   Package-Namespace Mapping  
Routine: IBDEI014

IBDEI014.m

Go to the documentation of this file.
IBDEI014 ; ; 04-NOV-2021
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 04, 2021
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1728,1,4,0)
 ;;=4^C85.22
 ;;^UTILITY(U,$J,358.3,1728,2)
 ;;=^5001713
 ;;^UTILITY(U,$J,358.3,1729,0)
 ;;=C85.23^^25^157^330
 ;;^UTILITY(U,$J,358.3,1729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1729,1,3,0)
 ;;=3^Mediastinal Large B-Cell Lymphoma,Intra-Abdominal Node
 ;;^UTILITY(U,$J,358.3,1729,1,4,0)
 ;;=4^C85.23
 ;;^UTILITY(U,$J,358.3,1729,2)
 ;;=^5001714
 ;;^UTILITY(U,$J,358.3,1730,0)
 ;;=C85.24^^25^157^325
 ;;^UTILITY(U,$J,358.3,1730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1730,1,3,0)
 ;;=3^Mediastinal Large B-Cell Lymphoma,Axilla/Upper Limb Node
 ;;^UTILITY(U,$J,358.3,1730,1,4,0)
 ;;=4^C85.24
 ;;^UTILITY(U,$J,358.3,1730,2)
 ;;=^5001715
 ;;^UTILITY(U,$J,358.3,1731,0)
 ;;=C85.25^^25^157^328
 ;;^UTILITY(U,$J,358.3,1731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1731,1,3,0)
 ;;=3^Mediastinal Large B-Cell Lymphoma,Ing Region/Lower Limb Node
 ;;^UTILITY(U,$J,358.3,1731,1,4,0)
 ;;=4^C85.25
 ;;^UTILITY(U,$J,358.3,1731,2)
 ;;=^5001716
 ;;^UTILITY(U,$J,358.3,1732,0)
 ;;=C85.26^^25^157^331
 ;;^UTILITY(U,$J,358.3,1732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1732,1,3,0)
 ;;=3^Mediastinal Large B-Cell Lymphoma,Intrapelvic Node
 ;;^UTILITY(U,$J,358.3,1732,1,4,0)
 ;;=4^C85.26
 ;;^UTILITY(U,$J,358.3,1732,2)
 ;;=^5001717
 ;;^UTILITY(U,$J,358.3,1733,0)
 ;;=C85.27^^25^157^333
 ;;^UTILITY(U,$J,358.3,1733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1733,1,3,0)
 ;;=3^Mediastinal Large B-Cell Lymphoma,Spleen
 ;;^UTILITY(U,$J,358.3,1733,1,4,0)
 ;;=4^C85.27
 ;;^UTILITY(U,$J,358.3,1733,2)
 ;;=^5001718
 ;;^UTILITY(U,$J,358.3,1734,0)
 ;;=C85.28^^25^157^332
 ;;^UTILITY(U,$J,358.3,1734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1734,1,3,0)
 ;;=3^Mediastinal Large B-Cell Lymphoma,Mult Site Nodes
 ;;^UTILITY(U,$J,358.3,1734,1,4,0)
 ;;=4^C85.28
 ;;^UTILITY(U,$J,358.3,1734,2)
 ;;=^5001719
 ;;^UTILITY(U,$J,358.3,1735,0)
 ;;=C85.29^^25^157^326
 ;;^UTILITY(U,$J,358.3,1735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1735,1,3,0)
 ;;=3^Mediastinal Large B-Cell Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,1735,1,4,0)
 ;;=4^C85.29
 ;;^UTILITY(U,$J,358.3,1735,2)
 ;;=^5001720
 ;;^UTILITY(U,$J,358.3,1736,0)
 ;;=C85.80^^25^157^425
 ;;^UTILITY(U,$J,358.3,1736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1736,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Unspec Site
 ;;^UTILITY(U,$J,358.3,1736,1,4,0)
 ;;=4^C85.80
 ;;^UTILITY(U,$J,358.3,1736,2)
 ;;=^5001721
 ;;^UTILITY(U,$J,358.3,1737,0)
 ;;=C85.81^^25^157^418
 ;;^UTILITY(U,$J,358.3,1737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1737,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Head/Face/Neck Node
 ;;^UTILITY(U,$J,358.3,1737,1,4,0)
 ;;=4^C85.81
 ;;^UTILITY(U,$J,358.3,1737,2)
 ;;=^5001722
 ;;^UTILITY(U,$J,358.3,1738,0)
 ;;=C85.82^^25^157^422
 ;;^UTILITY(U,$J,358.3,1738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1738,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Intrathoracic Node
 ;;^UTILITY(U,$J,358.3,1738,1,4,0)
 ;;=4^C85.82
 ;;^UTILITY(U,$J,358.3,1738,2)
 ;;=^5001723
 ;;^UTILITY(U,$J,358.3,1739,0)
 ;;=C85.83^^25^157^420
 ;;^UTILITY(U,$J,358.3,1739,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1739,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Intra-Abdominal Node
 ;;^UTILITY(U,$J,358.3,1739,1,4,0)
 ;;=4^C85.83
 ;;^UTILITY(U,$J,358.3,1739,2)
 ;;=^5001724
 ;;^UTILITY(U,$J,358.3,1740,0)
 ;;=C85.84^^25^157^416
 ;;^UTILITY(U,$J,358.3,1740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1740,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Axilla/Upper Limb Node
 ;;^UTILITY(U,$J,358.3,1740,1,4,0)
 ;;=4^C85.84
 ;;^UTILITY(U,$J,358.3,1740,2)
 ;;=^5001725
 ;;^UTILITY(U,$J,358.3,1741,0)
 ;;=C85.85^^25^157^419
 ;;^UTILITY(U,$J,358.3,1741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1741,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Ing Region/Lower Limb Node
 ;;^UTILITY(U,$J,358.3,1741,1,4,0)
 ;;=4^C85.85
 ;;^UTILITY(U,$J,358.3,1741,2)
 ;;=^5001726
 ;;^UTILITY(U,$J,358.3,1742,0)
 ;;=C85.86^^25^157^421
 ;;^UTILITY(U,$J,358.3,1742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1742,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Intrapelvic Node
 ;;^UTILITY(U,$J,358.3,1742,1,4,0)
 ;;=4^C85.86
 ;;^UTILITY(U,$J,358.3,1742,2)
 ;;=^5001727
 ;;^UTILITY(U,$J,358.3,1743,0)
 ;;=C85.87^^25^157^424
 ;;^UTILITY(U,$J,358.3,1743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1743,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Spleen
 ;;^UTILITY(U,$J,358.3,1743,1,4,0)
 ;;=4^C85.87
 ;;^UTILITY(U,$J,358.3,1743,2)
 ;;=^5001728
 ;;^UTILITY(U,$J,358.3,1744,0)
 ;;=C85.88^^25^157^423
 ;;^UTILITY(U,$J,358.3,1744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1744,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Mult Site Node
 ;;^UTILITY(U,$J,358.3,1744,1,4,0)
 ;;=4^C85.88
 ;;^UTILITY(U,$J,358.3,1744,2)
 ;;=^5001729
 ;;^UTILITY(U,$J,358.3,1745,0)
 ;;=C85.89^^25^157^417
 ;;^UTILITY(U,$J,358.3,1745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1745,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,1745,1,4,0)
 ;;=4^C85.89
 ;;^UTILITY(U,$J,358.3,1745,2)
 ;;=^5001730
 ;;^UTILITY(U,$J,358.3,1746,0)
 ;;=C85.90^^25^157^435
 ;;^UTILITY(U,$J,358.3,1746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1746,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,1746,1,4,0)
 ;;=4^C85.90
 ;;^UTILITY(U,$J,358.3,1746,2)
 ;;=^5001731
 ;;^UTILITY(U,$J,358.3,1747,0)
 ;;=C85.91^^25^157^428
 ;;^UTILITY(U,$J,358.3,1747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1747,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Head/Face/Neck Node
 ;;^UTILITY(U,$J,358.3,1747,1,4,0)
 ;;=4^C85.91
 ;;^UTILITY(U,$J,358.3,1747,2)
 ;;=^5001732
 ;;^UTILITY(U,$J,358.3,1748,0)
 ;;=C85.92^^25^157^432
 ;;^UTILITY(U,$J,358.3,1748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1748,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Intrathoracic Node
 ;;^UTILITY(U,$J,358.3,1748,1,4,0)
 ;;=4^C85.92
 ;;^UTILITY(U,$J,358.3,1748,2)
 ;;=^5001733
 ;;^UTILITY(U,$J,358.3,1749,0)
 ;;=C85.93^^25^157^430
 ;;^UTILITY(U,$J,358.3,1749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1749,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Intra-Abdominal Node
 ;;^UTILITY(U,$J,358.3,1749,1,4,0)
 ;;=4^C85.93
 ;;^UTILITY(U,$J,358.3,1749,2)
 ;;=^5001734
 ;;^UTILITY(U,$J,358.3,1750,0)
 ;;=C85.94^^25^157^426
 ;;^UTILITY(U,$J,358.3,1750,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1750,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Axilla/Upper Limb Node
 ;;^UTILITY(U,$J,358.3,1750,1,4,0)
 ;;=4^C85.94
 ;;^UTILITY(U,$J,358.3,1750,2)
 ;;=^5001735
 ;;^UTILITY(U,$J,358.3,1751,0)
 ;;=C85.95^^25^157^429
 ;;^UTILITY(U,$J,358.3,1751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1751,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Ing Region/Lower Limb Node
 ;;^UTILITY(U,$J,358.3,1751,1,4,0)
 ;;=4^C85.95
 ;;^UTILITY(U,$J,358.3,1751,2)
 ;;=^5001736
 ;;^UTILITY(U,$J,358.3,1752,0)
 ;;=C85.96^^25^157^431
 ;;^UTILITY(U,$J,358.3,1752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1752,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Intrapelvic Node
 ;;^UTILITY(U,$J,358.3,1752,1,4,0)
 ;;=4^C85.96
 ;;^UTILITY(U,$J,358.3,1752,2)
 ;;=^5001737
 ;;^UTILITY(U,$J,358.3,1753,0)
 ;;=C85.97^^25^157^434
 ;;^UTILITY(U,$J,358.3,1753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1753,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Spleen
 ;;^UTILITY(U,$J,358.3,1753,1,4,0)
 ;;=4^C85.97
 ;;^UTILITY(U,$J,358.3,1753,2)
 ;;=^5001738
 ;;^UTILITY(U,$J,358.3,1754,0)
 ;;=C85.98^^25^157^433
 ;;^UTILITY(U,$J,358.3,1754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1754,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Mult Site Nodes
 ;;^UTILITY(U,$J,358.3,1754,1,4,0)
 ;;=4^C85.98
 ;;^UTILITY(U,$J,358.3,1754,2)
 ;;=^5001739
 ;;^UTILITY(U,$J,358.3,1755,0)
 ;;=C85.99^^25^157^427
 ;;^UTILITY(U,$J,358.3,1755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1755,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,1755,1,4,0)
 ;;=4^C85.99
 ;;^UTILITY(U,$J,358.3,1755,2)
 ;;=^5001740
 ;;^UTILITY(U,$J,358.3,1756,0)
 ;;=C86.0^^25^157^139
 ;;^UTILITY(U,$J,358.3,1756,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1756,1,3,0)
 ;;=3^Extranodal NK/T-Cell Lymphoma,Nasal Type
 ;;^UTILITY(U,$J,358.3,1756,1,4,0)
 ;;=4^C86.0
 ;;^UTILITY(U,$J,358.3,1756,2)
 ;;=^5001741
 ;;^UTILITY(U,$J,358.3,1757,0)
 ;;=C86.2^^25^157^134
 ;;^UTILITY(U,$J,358.3,1757,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1757,1,3,0)
 ;;=3^Enteropathy-Type T-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,1757,1,4,0)
 ;;=4^C86.2
 ;;^UTILITY(U,$J,358.3,1757,2)
 ;;=^5001743
 ;;^UTILITY(U,$J,358.3,1758,0)
 ;;=C86.3^^25^157^480
 ;;^UTILITY(U,$J,358.3,1758,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1758,1,3,0)
 ;;=3^Subcutaneous Panniculitis-Like T-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,1758,1,4,0)
 ;;=4^C86.3
 ;;^UTILITY(U,$J,358.3,1758,2)
 ;;=^5001744
 ;;^UTILITY(U,$J,358.3,1759,0)
 ;;=C86.4^^25^157^68
 ;;^UTILITY(U,$J,358.3,1759,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1759,1,3,0)
 ;;=3^Blastic NK-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,1759,1,4,0)
 ;;=4^C86.4
 ;;^UTILITY(U,$J,358.3,1759,2)
 ;;=^5001745
 ;;^UTILITY(U,$J,358.3,1760,0)
 ;;=C86.5^^25^157^57
 ;;^UTILITY(U,$J,358.3,1760,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1760,1,3,0)
 ;;=3^Angioimmunoblastic T-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,1760,1,4,0)
 ;;=4^C86.5
 ;;^UTILITY(U,$J,358.3,1760,2)
 ;;=^5001746
 ;;^UTILITY(U,$J,358.3,1761,0)
 ;;=C86.6^^25^157^449
 ;;^UTILITY(U,$J,358.3,1761,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1761,1,3,0)
 ;;=3^Primary Cutaneous CD30-Positive T-Cell Proliferations
 ;;^UTILITY(U,$J,358.3,1761,1,4,0)
 ;;=4^C86.6
 ;;^UTILITY(U,$J,358.3,1761,2)
 ;;=^5001747
 ;;^UTILITY(U,$J,358.3,1762,0)
 ;;=C88.0^^25^157^482
 ;;^UTILITY(U,$J,358.3,1762,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1762,1,3,0)
 ;;=3^Waldenstrom Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,1762,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,1762,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,1763,0)
 ;;=C88.2^^25^157^213
 ;;^UTILITY(U,$J,358.3,1763,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1763,1,3,0)
 ;;=3^Heavy Chain Disease
 ;;^UTILITY(U,$J,358.3,1763,1,4,0)
 ;;=4^C88.2
 ;;^UTILITY(U,$J,358.3,1763,2)
 ;;=^55078
 ;;^UTILITY(U,$J,358.3,1764,0)
 ;;=C88.3^^25^157^235
 ;;^UTILITY(U,$J,358.3,1764,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1764,1,3,0)
 ;;=3^Immunoproliferative Small Intestinal Disease
 ;;^UTILITY(U,$J,358.3,1764,1,4,0)
 ;;=4^C88.3
 ;;^UTILITY(U,$J,358.3,1764,2)
 ;;=^61964
 ;;^UTILITY(U,$J,358.3,1765,0)
 ;;=C88.4^^25^157^138
 ;;^UTILITY(U,$J,358.3,1765,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1765,1,3,0)
 ;;=3^Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Assoc Lymphoid Tissue
 ;;^UTILITY(U,$J,358.3,1765,1,4,0)
 ;;=4^C88.4
 ;;^UTILITY(U,$J,358.3,1765,2)
 ;;=^5001749
 ;;^UTILITY(U,$J,358.3,1766,0)
 ;;=C88.8^^25^157^281
 ;;^UTILITY(U,$J,358.3,1766,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1766,1,3,0)
 ;;=3^Malig Immunoproliferative Diseases NEC
 ;;^UTILITY(U,$J,358.3,1766,1,4,0)
 ;;=4^C88.8
 ;;^UTILITY(U,$J,358.3,1766,2)
 ;;=^5001750
 ;;^UTILITY(U,$J,358.3,1767,0)
 ;;=C88.9^^25^157^282
 ;;^UTILITY(U,$J,358.3,1767,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1767,1,3,0)
 ;;=3^Malig Immunoproliferative Diseases,Unspec
 ;;^UTILITY(U,$J,358.3,1767,1,4,0)
 ;;=4^C88.9
 ;;^UTILITY(U,$J,358.3,1767,2)
 ;;=^5001751
 ;;^UTILITY(U,$J,358.3,1768,0)
 ;;=C90.00^^25^157^355
 ;;^UTILITY(U,$J,358.3,1768,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1768,1,3,0)
 ;;=3^Multiple Myeloma,Not in Remission
 ;;^UTILITY(U,$J,358.3,1768,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,1768,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,1769,0)
 ;;=C90.01^^25^157^354
 ;;^UTILITY(U,$J,358.3,1769,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1769,1,3,0)
 ;;=3^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,1769,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,1769,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,1770,0)
 ;;=C90.02^^25^157^353
 ;;^UTILITY(U,$J,358.3,1770,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1770,1,3,0)
 ;;=3^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,1770,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,1770,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,1771,0)
 ;;=C90.10^^25^157^448
 ;;^UTILITY(U,$J,358.3,1771,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1771,1,3,0)
 ;;=3^Plasma Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,1771,1,4,0)
 ;;=4^C90.10
 ;;^UTILITY(U,$J,358.3,1771,2)
 ;;=^5001754
 ;;^UTILITY(U,$J,358.3,1772,0)
 ;;=C90.11^^25^157^447
 ;;^UTILITY(U,$J,358.3,1772,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1772,1,3,0)
 ;;=3^Plasma Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,1772,1,4,0)
 ;;=4^C90.11
 ;;^UTILITY(U,$J,358.3,1772,2)
 ;;=^267517
 ;;^UTILITY(U,$J,358.3,1773,0)
 ;;=C90.12^^25^157^446
 ;;^UTILITY(U,$J,358.3,1773,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1773,1,3,0)
 ;;=3^Plasma Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,1773,1,4,0)
 ;;=4^C90.12
 ;;^UTILITY(U,$J,358.3,1773,2)
 ;;=^5001755
 ;;^UTILITY(U,$J,358.3,1774,0)
 ;;=C90.20^^25^157^137
 ;;^UTILITY(U,$J,358.3,1774,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1774,1,3,0)
 ;;=3^Extramedullary Plasmacytoma,Not in Remission
 ;;^UTILITY(U,$J,358.3,1774,1,4,0)
 ;;=4^C90.20
 ;;^UTILITY(U,$J,358.3,1774,2)
 ;;=^5001756
 ;;^UTILITY(U,$J,358.3,1775,0)
 ;;=C90.21^^25^157^136
 ;;^UTILITY(U,$J,358.3,1775,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1775,1,3,0)
 ;;=3^Extramedullary Plasmacytoma,In Remission
 ;;^UTILITY(U,$J,358.3,1775,1,4,0)
 ;;=4^C90.21
 ;;^UTILITY(U,$J,358.3,1775,2)
 ;;=^5001757
 ;;^UTILITY(U,$J,358.3,1776,0)
 ;;=C90.22^^25^157^135
 ;;^UTILITY(U,$J,358.3,1776,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1776,1,3,0)
 ;;=3^Extramedullary Plasmacytoma,In Relapse
 ;;^UTILITY(U,$J,358.3,1776,1,4,0)
 ;;=4^C90.22
 ;;^UTILITY(U,$J,358.3,1776,2)
 ;;=^5001758
 ;;^UTILITY(U,$J,358.3,1777,0)
 ;;=C90.30^^25^157^479
 ;;^UTILITY(U,$J,358.3,1777,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1777,1,3,0)
 ;;=3^Solitary Plasmacytoma,Not in Remission
 ;;^UTILITY(U,$J,358.3,1777,1,4,0)
 ;;=4^C90.30
 ;;^UTILITY(U,$J,358.3,1777,2)
 ;;=^5001759
 ;;^UTILITY(U,$J,358.3,1778,0)
 ;;=C90.31^^25^157^478
 ;;^UTILITY(U,$J,358.3,1778,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1778,1,3,0)
 ;;=3^Solitary Plasmacytoma,In Remission
 ;;^UTILITY(U,$J,358.3,1778,1,4,0)
 ;;=4^C90.31
 ;;^UTILITY(U,$J,358.3,1778,2)
 ;;=^5001760
 ;;^UTILITY(U,$J,358.3,1779,0)
 ;;=C90.32^^25^157^477
 ;;^UTILITY(U,$J,358.3,1779,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1779,1,3,0)
 ;;=3^Solitary Plasmacytoma,In Relapse
 ;;^UTILITY(U,$J,358.3,1779,1,4,0)
 ;;=4^C90.32
 ;;^UTILITY(U,$J,358.3,1779,2)
 ;;=^5001761
 ;;^UTILITY(U,$J,358.3,1780,0)
 ;;=C91.00^^25^157^9
 ;;^UTILITY(U,$J,358.3,1780,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1780,1,3,0)
 ;;=3^Acute Lymphoblastic Leumkemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,1780,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,1780,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,1781,0)
 ;;=C91.01^^25^157^8
 ;;^UTILITY(U,$J,358.3,1781,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1781,1,3,0)
 ;;=3^Acute Lymphoblastic Leumkemia,In Remission
 ;;^UTILITY(U,$J,358.3,1781,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,1781,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,1782,0)
 ;;=C91.02^^25^157^7
 ;;^UTILITY(U,$J,358.3,1782,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1782,1,3,0)
 ;;=3^Acute Lymphoblastic Leumkemia,In Relapse
 ;;^UTILITY(U,$J,358.3,1782,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,1782,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,1783,0)
 ;;=C91.10^^25^157^82
 ;;^UTILITY(U,$J,358.3,1783,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1783,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,1783,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,1783,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,1784,0)
 ;;=C91.11^^25^157^83
 ;;^UTILITY(U,$J,358.3,1784,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1784,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,1784,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,1784,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,1785,0)
 ;;=C91.12^^25^157^84
 ;;^UTILITY(U,$J,358.3,1785,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1785,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Relapse
 ;;^UTILITY(U,$J,358.3,1785,1,4,0)
 ;;=4^C91.12
 ;;^UTILITY(U,$J,358.3,1785,2)
 ;;=^5001767
 ;;^UTILITY(U,$J,358.3,1786,0)
 ;;=C91.30^^25^157^450
 ;;^UTILITY(U,$J,358.3,1786,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1786,1,3,0)
 ;;=3^Prolymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,1786,1,4,0)
 ;;=4^C91.30
 ;;^UTILITY(U,$J,358.3,1786,2)
 ;;=^5001768
 ;;^UTILITY(U,$J,358.3,1787,0)
 ;;=C91.31^^25^157^451
 ;;^UTILITY(U,$J,358.3,1787,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1787,1,3,0)
 ;;=3^Prolymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,1787,1,4,0)
 ;;=4^C91.31
 ;;^UTILITY(U,$J,358.3,1787,2)
 ;;=^5001769
 ;;^UTILITY(U,$J,358.3,1788,0)
 ;;=C91.32^^25^157^452
 ;;^UTILITY(U,$J,358.3,1788,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1788,1,3,0)
 ;;=3^Prolymphocytic Leukemia of B-Cell Type,In Relapse
 ;;^UTILITY(U,$J,358.3,1788,1,4,0)
 ;;=4^C91.32
 ;;^UTILITY(U,$J,358.3,1788,2)
 ;;=^5001770
 ;;^UTILITY(U,$J,358.3,1789,0)
 ;;=C91.40^^25^157^212
 ;;^UTILITY(U,$J,358.3,1789,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1789,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,1789,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,1789,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,1790,0)
 ;;=C91.41^^25^157^211
 ;;^UTILITY(U,$J,358.3,1790,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1790,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,1790,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,1790,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,1791,0)
 ;;=C91.42^^25^157^210
 ;;^UTILITY(U,$J,358.3,1791,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1791,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,1791,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,1791,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,1792,0)
 ;;=C91.50^^25^157^36
 ;;^UTILITY(U,$J,358.3,1792,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1792,1,3,0)
 ;;=3^Adult T-Cell Lymphoma/Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,1792,1,4,0)
 ;;=4^C91.50
 ;;^UTILITY(U,$J,358.3,1792,2)
 ;;=^5001774
 ;;^UTILITY(U,$J,358.3,1793,0)
 ;;=C91.51^^25^157^35
 ;;^UTILITY(U,$J,358.3,1793,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1793,1,3,0)
 ;;=3^Adult T-Cell Lymphoma/Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,1793,1,4,0)
 ;;=4^C91.51
 ;;^UTILITY(U,$J,358.3,1793,2)
 ;;=^5001775
 ;;^UTILITY(U,$J,358.3,1794,0)
 ;;=C91.52^^25^157^34
 ;;^UTILITY(U,$J,358.3,1794,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1794,1,3,0)
 ;;=3^Adult T-Cell Lymphoma/Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,1794,1,4,0)
 ;;=4^C91.52
 ;;^UTILITY(U,$J,358.3,1794,2)
 ;;=^5001776
 ;;^UTILITY(U,$J,358.3,1795,0)
 ;;=C91.60^^25^157^453
 ;;^UTILITY(U,$J,358.3,1795,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1795,1,3,0)
 ;;=3^Prolymphocytic Leukemia of T-Cell Type,Not in Remission